What was recalled
The U.S. Food and Drug Administration (FDA) has issued a Class II recall affecting a specific pharmaceutical product distributed by Hospira, Inc., which operates under the Pfizer brand umbrella. This action centers on Dopamine HCl Injection, USP, formulated at a concentration of 200 mg per 5 mL, which equates to 40 mg/mL. The product is packaged as single-dose vials, each containing 5 mL of solution. These vials are typically arranged in trays of 25 for clinical or institutional use. It is important to note that this medication is available only by prescription (Rx only), meaning it is not a standard over-the-counter item found on retail shelves but rather a specialized drug used primarily in controlled medical settings.
The specific batch subject to this recall is identified by Lot Number NL5230. This lot has an expiration date of October 2027, indicating that the product was relatively new and had not yet reached its end-of-life window when the recall was initiated. The physical packaging includes vials with National Drug Code (NDC) 0409-5820-11 and cartons bearing NDC 0409-5820-01. Healthcare providers, pharmacists, and hospital inventory managers should carefully check their stock against these specific identifiers to determine if they hold any units from this particular lot.
This recall was officially announced on September 4, 2026. The distribution pattern for the affected product was nationwide across the United States, meaning that hospitals, clinics, and pharmacies in all states could potentially have received this stock. However, the FDA’s records specifically highlight New York (NY) as a state of interest or origin for this particular recall notification, though the product itself was distributed broadly. Because Dopamine HCl is a critical medication often used in emergency medicine, intensive care units, and cardiac care to manage blood pressure and heart rate, even a limited distribution of a compromised batch can have significant implications for patient safety protocols.
The company responsible for distributing this specific lot is Hospira, Inc., located in Lake Forest, Illinois (60045 USA). As the distributor, Hospira bears the responsibility for initiating the recall and coordinating with healthcare facilities to retrieve the product. The classification of this recall as Class II indicates that use of or exposure to the violative product may cause temporary, medically reversible, serious adverse health consequences, or where the probability of serious adverse health consequences is remote. This underscores the seriousness of the situation without implying an immediate, fatal threat in every instance, but rather highlighting a significant quality control failure that requires prompt attention.
The hazard, explained
When you see a recall classified as involving a "Lack of Assurance of Sterility," it is important to understand exactly what that means for the safety of the medication in your hands. In simple terms, this phrase indicates that Pfizer’s quality control testing or manufacturing processes did not successfully confirm that these specific vials of Dopamine HCl Injection are free from living microorganisms. While the drug itself—Dopamine Hydrochloride—is a vital and effective medication used to treat low blood pressure and heart failure, its safety relies entirely on the container remaining perfectly sealed and sterile from the moment it leaves the factory until it reaches the patient.
Sterility is not just a preference for injectable drugs; it is a strict medical requirement. Because Dopamine HCl Inj., USP is administered directly into the bloodstream via intravenous injection, bypassing the body’s natural physical barriers like skin and stomach acid, any bacteria, mold, or fungi present in the vial would enter the circulatory system immediately. The "lack of assurance" noted in this FDA recall means that during routine testing or manufacturing validation for Lot # NL5230, the company could not guarantee that these 25-vial trays met the rigorous standards required to prove zero microbial contamination. This does not necessarily mean every single vial is contaminated, but rather that the process failed to provide the mathematical certainty required by federal regulations that they are safe.
Why is this so dangerous? The human body has robust defenses against germs in the air or on surfaces, but the bloodstream is a different environment. When microorganisms enter the blood directly, they can multiply rapidly without obstruction. This can lead to serious systemic infections, such as bacteremia (bacteria in the blood) or sepsis, which is a life-threatening response to infection that can cause tissue damage, organ failure, and even death. For patients who are already critically ill—often those with compromised immune systems or severe cardiac issues—the introduction of even a small number of pathogens can be catastrophic.
It is also worth noting the nature of the distribution pattern for this recall. The affected product was distributed nationwide across the United States, meaning hospitals, clinics, and pharmacies in New York and many other states may have received these vials. Because the drug is a prescription-only (Rx) item typically handled by medical professionals, the risk is concentrated in clinical settings where the medication is prepared for immediate use. However, the uncertainty of sterility means that even if the vial looks clear and colorless, it could still harbor invisible threats. The FDA’s classification of this as a Class II recall suggests that while use of the product might cause temporary health problems or serious injury, it is unlikely to cause death, but the potential for harm remains significant enough to warrant immediate removal from shelves and medical stockrooms.
Who is most at risk
When we talk about a Class II recall involving an intravenous medication like Dopamine HCl, it is important to understand that the primary "risk" here is not one of accidental ingestion by the general public, such as a child finding a bottle in a pantry. Instead, the individuals at risk are patients who are actively receiving this specific medication in a clinical setting. Dopamine is a potent drug used primarily in emergency and critical care situations to treat severe hypotension (dangerously low blood pressure) or shock. Therefore, the people most vulnerable to the consequences of this recall are those who are already critically ill, often in intensive care units (ICUs), operating rooms, or emergency departments. These patients are typically on life-support systems or have compromised cardiovascular systems, making them uniquely sensitive to any deviation in medication quality.
The core hazard identified in this recall is a "Lack of Assurance of Sterility." In the world of injectable drugs, sterility is non-negotiable. Because Dopamine HCl is administered directly into the bloodstream via an intravenous line, it bypasses the body’s natural barriers, such as the skin and the digestive system, which normally protect against bacteria and other pathogens. If a vial from Lot NL5230 is not truly sterile, it may contain microorganisms that are invisible to the naked eye. For a healthy person, exposure to a tiny amount of bacteria might result in nothing or a minor local reaction. However, for the patient using this drug, the risk is systemic infection, known as sepsis. Sepsis is a life-threatening response to infection that can lead to tissue damage, organ failure, and death. The patients most at risk are those whose immune systems are already weakened by their underlying conditions, surgery, or other treatments, leaving them with little ability to fight off an infection introduced directly into their blood.
Furthermore, the nature of Dopamine administration adds another layer of complexity. This drug is often given in continuous, high-precision infusions. If a patient is receiving this medication for an extended period, any contamination in the vial could lead to a sustained introduction of pathogens into the bloodstream. The risk is not limited to just the moment of injection; it extends throughout the duration of the treatment. While the recall notice does not specify that any incidents have occurred yet, the potential for harm is significant because the drug is intended for use in the most fragile members of our healthcare system. It is also worth noting that this product is distributed by Hospira, Inc., and was available nationwide, meaning hospitals across New York and other states could potentially be holding stock from this specific lot. Healthcare providers must be vigilant not just for the health of the patient, but for the integrity of the supply chain, as the error lies in the manufacturing assurance process rather than in how the drug is used once it reaches the bedside.
How to tell if you have the recalled item
When a recall involves prescription medication, identifying the correct product requires careful attention to detail because many drugs look similar at first glance. To determine whether you possess the specific batch affected by this FDA notice, you need to verify several distinct pieces of information printed on the packaging. This process is not about guessing; it is about matching the concrete data points provided in the official recall record against the physical items in your possession.
First, confirm the medication name and manufacturer. You are looking for Dopamine HCl Inj., USP. It is important to note that while the recall is issued by the FDA, the brand listed is Pfizer, but the product was distributed by Hospira, Inc., located in Lake Forest, IL. If your vial was supplied by a different distributor or carries a different brand name, it is likely not part of this specific recall event.
The most critical identifiers are the National Drug Code (NDC) numbers and the lot number. These act as the unique fingerprint for this batch of medication. You must check both the outer carton and the individual vial label. The recalled items carry the following NDCs:
- Vial NDC: 0409-5820-11
- Carton NDC: 0409-5820-01
If your product has any other NDC number, it is not included in this recall. Next, locate the Lot number. The specific lot identified in this recall is NL5230. This code is typically printed on the side of the carton or near the expiration date on the vial label. If your lot number differs from NL5230, you do not have the recalled product.
Additionally, verify the expiration date. The affected lot has an expiration date of 10/2027. While a future expiration date might suggest freshness, in the context of this recall, it is a key matching criterion for Lot NL5230. Also, note the dosage strength: this recall applies specifically to 200 mg/5 mL (which equals 40 mg/mL) in 5 mL single-dose vials, sold in trays of 25.
If you are a healthcare provider or patient who received these items through nationwide distribution in New York or elsewhere in the U.S., and your product matches all the above criteria—Pfizer/Hospira branding, NDCs 0409-5820-11 (vial) and 0409-5820-01 (carton), Lot NL5230, and Exp 10/2027—you have the recalled item. If any detail does not match, your product is safe from this specific recall action.
What to do — step by step
Because the FDA has issued a Class II recall for this specific Pfizer-distributed Dopamine HCl injection due to a lack of assurance of sterility, taking immediate and careful action is essential. Sterility is not just a technical requirement for injectable drugs; it is the primary barrier against life-threatening infections like sepsis or local abscesses when medication enters the bloodstream directly. Since the official remedy details were not explicitly stated in the recall notice, you must rely on standard medical safety protocols and direct communication with the distributor to ensure your health is protected. Here is how to handle this situation safely and effectively.
- Stop using the product immediately. If you are a healthcare provider or a patient who has been prescribed this medication, do not administer any remaining doses from Lot # NL5230. The risk of infection outweighs any potential benefit because the manufacturing process failed to guarantee that the vials are free from harmful microorganisms. Dispose of any unused portions according to your facility’s hazardous waste protocols or local pharmacy return guidelines, but keep the packaging intact for identification purposes.
- Verify your inventory carefully. Check every vial and carton against the specific details provided in the recall. You are looking for NDC 0409-5820-11 (vial) and NDC 0409-5820-01 (carton), distributed by Hospira, Inc., located in Lake Forest, IL. Confirm that the lot number is exactly NL5230 and that the expiration date is 10/2027. Even if the drug appears clear and undamaged, the sterility assurance defect means it cannot be used safely.
- Contact the distributor or your supplier. Since Pfizer is the brand name but Hospira, Inc. is listed as the distributor, you should reach out to them directly to report your possession of this lot. They will provide specific instructions on how to return the product for credit or destruction. If you are a patient, contact your prescribing doctor and pharmacy immediately. Do not attempt to return it yourself unless instructed; they will arrange for a safe exchange or alternative prescription.
- Monitor for adverse effects. If you have already received a dose from this lot before the recall was announced, watch closely for signs of infection at the injection site or systemic symptoms such as fever, chills, redness, swelling, or pain. These could indicate an introduction of bacteria into your body due to the sterility failure. Seek medical attention promptly if you experience any of these symptoms, and inform your provider that you received a recalled lot.
- Document everything. Keep records of when you stopped use, who you contacted, and what instructions were given. This helps ensure that the recall process is tracked correctly and that you receive any applicable refunds or replacements without delay.
By following these steps, you help ensure that unsafe medication does not reach a patient and that your health remains the top priority during this recall event.
Your refund, repair, or replacement options
When a pharmaceutical recall occurs, the most immediate concern for patients and healthcare providers is often not just the safety risk, but also the logistical and financial question of what happens next. In this specific instance involving Pfizer’s Dopamine HCl Injection, USP, the official FDA recall documentation does not explicitly state the specific remedy or return process. This absence of a stated remedy in the public record can feel unsettling, but it is important to understand what this means for you and how to navigate the situation with confidence.
First, it is crucial to clarify that drugs cannot be "repaired" in the way a mechanical device might be. Once a pharmaceutical product has been manufactured and distributed, especially one classified as Class II due to a lack of assurance of sterility, there is no process for fixing or re-certifying the product for medical use. Therefore, the concept of a repair is not applicable here. The only viable options are typically return, destruction, or replacement with a verified safe batch, depending on who holds the inventory.
If you are a patient who has already received this medication, you should not attempt to keep it or use it under any circumstances. However, because the recall notice does not provide direct contact information for patients (such as a dedicated 1-800 number for consumers), your path forward depends on where the drug is currently located. If the product is still in the possession of a hospital, clinic, or pharmacy, the institution is legally responsible for managing the return or destruction of the stock. They will have received direct communication from Pfizer or Hospira, Inc., the distributor, regarding how to handle the lots NL5230 expiring in 10/2027. You do not need to contact anyone directly; your healthcare provider’s pharmacy department will handle the logistics of replacing the medication with a safe alternative.
If you are a healthcare facility or distributor that still holds inventory of Vial NDC 0409-5820-11 or Carton NDC 0409-5820-01, you must act quickly. Since the remedy is not stated in the general recall alert, you should immediately contact your sales representative for Pfizer or Hospira, Inc., located in Lake Forest, IL. They will provide specific instructions on whether to return the vials for a credit or how to safely dispose of them. Do not attempt to sell or transfer this stock to another party.
For those worried about financial loss, it is important to note that Class II recalls are taken seriously by manufacturers like Pfizer. While the public notice does not guarantee a refund, companies typically offer credits for returned goods to maintain trust and comply with regulatory expectations. However, because the specific terms are not detailed in this FDA alert, you must rely on direct communication from the distributor for any financial reconciliation. Your primary focus should remain on patient safety: ensure no doses of Lot NL5230 are administered, and secure the remaining vials away from clinical areas until you receive further instructions from your supplier.
What can happen if you ignore it
When a pharmaceutical product is recalled due to a "lack of assurance of sterility," the primary concern is not that the medication itself is chemically wrong, but rather that it may be contaminated with microorganisms. Dopamine Hydrochloride is a potent vasopressor used to treat low blood pressure and shock, typically administered intravenously in critical care settings. Because this drug bypasses the body’s natural external barriers (like skin) and enters directly into the bloodstream, any contamination present in the vial can have immediate and severe systemic consequences. Ignoring the recall and continuing to use these specific vials from Lot NL5230 exposes patients to a significant risk of sepsis, which is a life-threatening reaction to an infection.
Sepsis occurs when the body’s response to an infection goes into overdrive, causing widespread inflammation that can damage multiple organ systems. In the context of an intravenous drug like dopamine, the path of entry for bacteria or fungi is direct and rapid. If a vial lacks proper sterilization assurance, it may harbor organisms such as Staphylococcus, Pseudomonas, or various fungi. When injected, these pathogens do not need to breach skin barriers; they are introduced directly into the circulatory system. This can lead to bacteremia (bacteria in the blood) or fungemia, which can quickly progress to septic shock. Septic shock is a medical emergency where blood pressure drops dangerously low, preventing enough blood from reaching vital organs like the kidneys, liver, and heart.
The consequences of ignoring this recall extend beyond immediate infection. Patients who receive contaminated dopamine may require prolonged hospital stays, intensive care unit (ICU) admission, and aggressive treatment with broad-spectrum antibiotics or antifungal medications. In severe cases, particularly for immunocompromised patients or those already critically ill from the condition being treated with dopamine, this additional infection can be fatal. Even if survival is achieved, there is a risk of long-term complications, such as organ damage or the development of antibiotic-resistant infections, which are difficult to treat and require specialized care.
It is crucial to understand that contamination does not always present with obvious signs. A vial might look clear and colorless, with no visible particles, yet still contain harmful microorganisms. The FDA’s classification of this as a Class II recall indicates that use or exposure to the product may cause temporary or medically reversible health problems, but in the worst-case scenarios involving sepsis, the outcome can be permanent or fatal. Therefore, the risk is not theoretical; it is a direct threat to patient safety that cannot be mitigated by visual inspection alone. Continuing to use these vials gambles with the patient’s life for no medical benefit, as safe, sterile alternatives are available.